evidence table

Nac Cognition Randomized Trial Evidence Table

Name: Nac Cognition Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Nac Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Nac Cognition Randomized Trial	The executive function composite score improved over time (B = 0.31, 95% CI = [0.14, 0.48], p < 0.001), with no significant differences between N-acetylcysteine and placebo (B = -0.04, 95% CI = -0.28 to 0.20, p = 0.8) or in other cognitive domains.	2	Gallagher D (2026)	Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial.
Nac Cognition Randomized Trial	CONCLUSION: N-acetylcysteine supplementation did not provide additional cognitive benefits beyond that of cardiac rehabilitation alone among patients with vascular mild cognitive impairment.	2	Gallagher D (2026)	Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial.
Nac Cognition Randomized Trial	BACKGROUND: Oxidative stress is implicated in the etiology of mild cognitive impairment.	2	Gallagher D (2026)	Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial.
Nac Cognition Randomized Trial	We hypothesized that oral supplementation with N-acetylcysteine, a precursor to the antioxidant glutathione, would improve cognitive outcomes among individuals with mild cognitive impairment.	2	Gallagher D (2026)	Efficacy and safety of N-acetylcysteine in patients with mild cognitive impairment undergoing exercise-based cardiac rehabilitation program: a randomized controlled trial.
Nac Cognition Randomized Trial	1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults ().	3	Wang Xiaolan (2026)	Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Nac Cognition Randomized Trial	1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence ().	3	Wang Xiaolan (2026)	Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Nac Cognition Randomized Trial	Low circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,).	3	Wang Xiaolan (2026)	Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults
Nac Cognition Randomized Trial	In this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials.	3	Wang Xiaolan (2026)	Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults